These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 38771862)
1. The politics and governance of drug production in public-private partnerships: Brazil de Moraes Achcar H; da Fonseca EM Glob Public Health; 2024 Jan; 19(1):2350654. PubMed ID: 38771862 [TBL] [Abstract][Full Text] [Related]
2. Brazil's Fight against Hepatitis C - Universalism, Local Production, and Patents. da Fonseca EM; Shadlen K; Bastos FI N Engl J Med; 2019 Feb; 380(7):605-607. PubMed ID: 30763192 [No Abstract] [Full Text] [Related]
3. Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind. Grillon C; Krishtel PR; Mellouk O; Basenko A; Freeman J; Mendão L; Andrieux-Meyer I; Morin S J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25060. PubMed ID: 29633580 [TBL] [Abstract][Full Text] [Related]
4. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness? Assefa Y; Hill PS; Ulikpan A; Williams OD Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757 [TBL] [Abstract][Full Text] [Related]
5. The politics of COVID-19 vaccination in middle-income countries: Lessons from Brazil. Fonseca EMD; Shadlen KC; Bastos FI Soc Sci Med; 2021 Jul; 281():114093. PubMed ID: 34144480 [TBL] [Abstract][Full Text] [Related]
6. Public procurement of hepatitis C medicines in Brazil from 2005 to 2015. Chaves GC; Castro CGSO; Oliveira MA Cien Saude Colet; 2017 Aug; 22(8):2527-2538. PubMed ID: 28793069 [TBL] [Abstract][Full Text] [Related]
7. Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals. Hill A; Tahat L; Mohammed MK; Tayyem RF; Khwairakpam G; Nath S; Freeman J; Benbitour I; Helmy S J Virus Erad; 2018 Apr; 4(2):128-131. PubMed ID: 29682307 [TBL] [Abstract][Full Text] [Related]
8. Brazil's fight against AIDS and its implications for global health governance. Wogart JP; Calcagnotto G Healthc Q; 2006; 9(1):76-89. PubMed ID: 16548439 [TBL] [Abstract][Full Text] [Related]
9. The production and R&D structure of the Brazilian pharmaceutical industry: the role of public procurement and public drug production. Sorte Junior WF Glob Public Health; 2012; 7(10):1062-79. PubMed ID: 22950510 [TBL] [Abstract][Full Text] [Related]
10. Expanding drug access in Brazil: lessons for Latin America and Canada. Cohen JC Can J Public Health; 2006; 97(6):I15-8. PubMed ID: 17203728 [TBL] [Abstract][Full Text] [Related]
11. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145 [TBL] [Abstract][Full Text] [Related]
12. Production of antiretroviral drugs in middle- and low-income countries. Pinheiro Edos S; Brüning K; Macedo MF; Siani AC Antivir Ther; 2014; 19 Suppl 3():49-55. PubMed ID: 25310755 [TBL] [Abstract][Full Text] [Related]
13. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Hill A; Khoo S; Fortunak J; Simmons B; Ford N Clin Infect Dis; 2014 Apr; 58(7):928-36. PubMed ID: 24399087 [TBL] [Abstract][Full Text] [Related]
14. How Brazil's President turned the country into a global epicenter of COVID-19. Ferrante L; Duczmal L; Steinmetz WA; Almeida ACL; Leão J; Vassão RC; Tupinambás U; Fearnside PM J Public Health Policy; 2021 Sep; 42(3):439-451. PubMed ID: 34453095 [TBL] [Abstract][Full Text] [Related]
15. Corporate social responsibility to improve access to medicines: the case of Brazil. Thorsteinsdóttir H; Ovtcharenko N; Kohler JC Global Health; 2017 Feb; 13(1):10. PubMed ID: 28222793 [TBL] [Abstract][Full Text] [Related]
16. How Brazil outpaced the United States when it came to AIDS: the politics of civic infiltration, reputation, and strategic internationalization. Gómez EJ J Health Polit Policy Law; 2011 Apr; 36(2):317-52. PubMed ID: 21543708 [TBL] [Abstract][Full Text] [Related]
17. [Vulnerabilities of Brazil's domestic pharmaceutical and biotech industry in the context of the COVID-19 pandemic]. Fernandes DRA; Gadelha CAG; Maldonado JMSV Cad Saude Publica; 2021; 37(4):e00254720. PubMed ID: 33886709 [TBL] [Abstract][Full Text] [Related]
19. How can a policy foster local pharmaceutical production and still protect public health? Lessons from the health-industry complex in Brazil. da Fonseca EM Glob Public Health; 2018 Apr; 13(4):489-502. PubMed ID: 29098942 [TBL] [Abstract][Full Text] [Related]
20. Role Of Generics In Treatment Of Hepatitis C Infection. Umar M; Akhter TS; Akbar I; Nisar G; Osama M; Akhter TS J Ayub Med Coll Abbottabad; 2016; 28(4 Suppl 1):S890-S894. PubMed ID: 28782339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]